Andrzej T Slominski, Tae-Kang Kim, Zorica Janjetovic, Radomir M Slominski, Gitali Ganguli-Indra, Mohammad Athar, Arup K Indra, Russel J Reiter, Konrad Kleszczyński
{"title":"Melatonin and the Skin: Current Progress and Perspectives for Human Health.","authors":"Andrzej T Slominski, Tae-Kang Kim, Zorica Janjetovic, Radomir M Slominski, Gitali Ganguli-Indra, Mohammad Athar, Arup K Indra, Russel J Reiter, Konrad Kleszczyński","doi":"10.1016/j.jid.2024.11.012","DOIUrl":null,"url":null,"abstract":"<p><p>Skin has the capacity to produce and metabolize melatonin into biologically active metabolites. These metabolites exert phenotypic activities through receptor-dependent and receptor-independent action, including direct antioxidant activity, interaction with regulatory proteins, and regulation of mitochondrial function. They can act on G-protein-coupled melatonin receptors (MT1 and MT2) as well as nuclear aryl hydrocarbon receptor and peroxisome proliferator-activated receptor γ receptors. These metabolic pathways, together with receptor- and nonreceptor-mediated phenotypic activities of its intermediates, has been identified as a cutaneous melatoninergic system. Its pharmacological modulation and topical application of melatonin or its metabolites can be used to prevent and treat skin disorders and cutaneous aging.</p>","PeriodicalId":94239,"journal":{"name":"The Journal of investigative dermatology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of investigative dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.jid.2024.11.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Skin has the capacity to produce and metabolize melatonin into biologically active metabolites. These metabolites exert phenotypic activities through receptor-dependent and receptor-independent action, including direct antioxidant activity, interaction with regulatory proteins, and regulation of mitochondrial function. They can act on G-protein-coupled melatonin receptors (MT1 and MT2) as well as nuclear aryl hydrocarbon receptor and peroxisome proliferator-activated receptor γ receptors. These metabolic pathways, together with receptor- and nonreceptor-mediated phenotypic activities of its intermediates, has been identified as a cutaneous melatoninergic system. Its pharmacological modulation and topical application of melatonin or its metabolites can be used to prevent and treat skin disorders and cutaneous aging.